What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?

What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer?

To determine whether the post-external beam radiotherapy (RT) prostate-specific antigen nadir (nPSA) improves our ability to predict freedom from PSA failure, progression-free survival (PFS), and overall survival. Controversy regarding the importance of nPSA after external beam RT as a prognostic in...

Full description

Saved in:
Bibliographic Details
Published in:Urology (Ridgewood, N.J.) Vol. 62; no. 3; pp. 492 - 496
Main Authors: DeWitt, K.D, Sandler, H.M, Weinberg, V, McLaughlin, P.W, Roach, M
Format: Journal Article
Language:English
Published: New York, NY Elsevier Inc 01-09-2003
Elsevier Science
Subjects:
Adenocarcinoma - diagnosis
Adenocarcinoma - mortality
Adenocarcinoma - radiotherapy
Age Factors
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - analysis
Disease-Free Survival
Follow-Up Studies
Humans
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Staging
Nephrology. Urinary tract diseases
Prostate-Specific Antigen - analysis
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - mortality
Prostatic Neoplasms - radiotherapy
Risk Assessment
Survival Rate
Treatment Failure
Tumors of the urinary system
Urinary tract. Prostate gland
Human
Nadir
Urinary system disease
Prostate disease
Survivor
Prediction
Early stage
Tumoral marker
Malignant tumor
Prostate specific antigen
Antigen
Male genital diseases
Prostate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine whether the post-external beam radiotherapy (RT) prostate-specific antigen nadir (nPSA) improves our ability to predict freedom from PSA failure, progression-free survival (PFS), and overall survival. Controversy regarding the importance of nPSA after external beam RT as a prognostic indicator for patients with localized prostate cancer has continued. This analysis was based on the data from 748 patients with low and intermediate-risk localized prostate cancer treated with external beam RT alone. Patients were categorized by nPSA quartile groups with cutpoints of less than 0.3, 0.3 to less than 0.6, 0.6 to less than 1.2, and 1.2 ng/mL or greater. Both univariate and multivariate analyses were used to determine the significance of nPSA on PSA failure (American Society for Therapeutic Radiology Oncology consensus definition), PFS (death after PSA failure), and overall survival (death from any cause). Freedom from PSA failure was strongly associated with nadir quartile groups (P <0.0001). PFS was also significantly different statistically among nadir quartile groups (P = 0.02). No statistically significant difference was found in overall survival associated with nPSA at this point. nPSA is a strong independent predictor of freedom from PSA failure and PFS in patients with low and intermediate-risk localized prostate cancer treated with RT alone. Longer follow-up and larger patient numbers are required to confirm these observations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-4295
1527-9995
DOI:10.1016/S0090-4295(03)00460-6